ADC Therapeutics (ADCT) grants 221,100 RSUs to Chief Legal Officer

Rhea-AI Filing Summary

GRAHAM PETER J reported acquisition or exercise transactions in this Form 4 filing.

ADC Therapeutics disclosed that Chief Legal Officer Peter J. Graham received an award of 221,100 restricted stock units (RSUs) of common shares on June 30, 2026 under an incentive award letter agreement. The RSUs vest on the earlier of June 30, 2027 or certain termination events, subject to continued employment. Each RSU represents a right to receive one common share, bringing his direct holdings to 841,640 common shares after the award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GRAHAM PETER J

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	221,100	$0.00	--

Holdings After Transaction: Common Shares — 841,640 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU award size: 221,100 shares Grant price per share: $0.00 per share Shares after transaction: 841,640 shares +2 more

5 metrics

RSU award size 221,100 shares Restricted stock units granted on June 30, 2026

Grant price per share $0.00 per share RSU grant to Chief Legal Officer

Shares after transaction 841,640 shares Total common shares directly held after RSU award

RSU grant date June 30, 2026 Date RSUs were granted under incentive award letter

RSU vesting date June 30, 2027 Vests on earlier of this date or qualifying termination

Key Terms

restricted stock units ("RSUs"), incentive award letter agreement, vest upon the earlier of, termination of employment by the Issuer without cause, +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents an award of restricted stock units ("RSUs") granted on June 30, 2026"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

incentive award letter agreement financial

"RSUs granted on June 30, 2026 pursuant to an incentive award letter agreement"

vest upon the earlier of financial

"The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment"

termination of employment by the Issuer without cause financial

"or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason"

good reason financial

"termination of employment by the Issuer without cause or by the reporting person for good reason"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 05:17 PM Accepted by SEC EDGAR 07/02/2026 - 05:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GRAHAM PETER J

(Last) (First) (Middle)

430 MOUNTAIN AVENUE, SUITE 404

(Street)

NEW PROVIDENCE NEW JERSEY 07974

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ADC Therapeutics SA [ ADCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/30/2026		A	V	221,100(1)	A	$0	841,640	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units ("RSUs") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Remarks:

	/s/ Lisa Kallebo, Attorney-in-Fact for Peter Graham	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ADC Therapeutics (ADCT) report in this filing?

ADC Therapeutics reported that Chief Legal Officer Peter J. Graham received an award of 221,100 restricted stock units. These RSUs were granted on June 30, 2026 under an incentive award letter agreement as part of his compensation in common shares.

How many ADC Therapeutics (ADCT) shares does Peter J. Graham hold after this RSU grant?

After the award, Peter J. Graham holds 841,640 common shares of ADC Therapeutics directly. This figure includes the effect of the 221,100 restricted stock units granted on June 30, 2026 as reported in the insider transaction filing.

When do the new RSUs granted by ADC Therapeutics (ADCT) to its CLO vest?

The RSUs vest on the earlier of June 30, 2027 or termination of employment by ADC Therapeutics without cause, or by Peter J. Graham for good reason. Vesting also requires that he remain employed with the company on the vesting date.

What does each RSU granted by ADC Therapeutics (ADCT) represent in this Form 4?

Each restricted stock unit granted to Peter J. Graham represents a contingent right to receive one common share of ADC Therapeutics. The award therefore corresponds to up to 221,100 common shares, subject to satisfaction of the vesting and employment conditions described.

Is the ADC Therapeutics (ADCT) insider transaction a market purchase or a compensation grant?

The transaction is a compensation-related grant, not a market purchase. Peter J. Graham received 221,100 restricted stock units at a price of $0.00 per share as part of an incentive award, rather than buying shares on the open market.